Cite
HARVARD Citation
Woodcock, M. et al. (n.d.). 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. Journal for immunotherapy of cancer. pp. A281-A282. [Online].